Glenmark Pharma receives ANDA nod for Topiramate Extended-Release Capsules

Glenmark Pharma receives ANDA nod for Topiramate Extended-Release Capsules

by admin- Wednesday, February 3rd, 2021 04:22:38 PM

Glenmark Pharmaceuticals (Glenmark) has acquired very last approval by using the US Food & Drug Administration (USFDA) for Topiramate Extended-Release Capsules, 25 mg, 50 mg, a hundred mg, 150 mg, and 2 hundred mg, the normal model of Qudexy 1 XR Capsules, 25 mg, 50 mg, one hundred mg, one hundred fifty mg, and 2 hundred mg, of Upsher-Smith Laboratories, LLC.

News Updates